

Box Seg/GP
CAU 14/5/10
Patents

Attorney Docket No. 07826-0007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Adermann, Knut et al.

Application No.

08/817,547

Filed:

March 27, 1997

For:

PEPTIDES FROM THE HPTH

**SEQUENCE** 

Assistant Commissioner of Patents Washington, DC 20231

RECEIVED

APR 0 2 1998

MATRIX CUSTOMER SERVICE CENTER

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES.AND STATEMENT UNDER 37 C.F.R. §§ 1.825(A) AND 1.825(B)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 27, 1998, a diskette containing the Sequence Listing in computer-readable form is enclosed along with a substitute paper copy.

Pursuant to 37 C.F.R. §1.821(e), the copy of the sequence listing in computer readable form and substitute paper copy are identical to the sequence listing contained in the application as filed and numbered sequentially as page numbers 11 through 25. Transmitted herewith are substitute pages 11-25. Please remove pages 11-25 as filed on February 2, 1997, and replace with the substitute pages submitted herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231, on March 25, 1898.

Mary Anthony Merchant, Ph.D.-Reg. No. 39,771

No new matter has been added and the diskette is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

> Respectfully submitted, JONES & ASKEW, LLP

Mary Anthony Merchant, Ph.D. Registration No. 39,771 By:

Jones & Askew, LLP 37th Floor 191 Peachtree Street, N.E. Atlanta, Georgia 30303-1769 (404) 818-3700 Attorney Docket No. 07826-0007 Application No.: 08/817,547
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
TIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

N

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	<ol> <li>The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> </ol>
	<ol><li>The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</li></ol>
X	7. Other: The General Information Section of the listing needs to be corrected. See attached.
Applicant Must Provide:	
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
	Rules Interpretation, call (703) 308-4216
	CRF Submission Help, call (703) 308-4212 Patentln software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE